Vir Biotechnology reported a significant increase in total revenues to $238.7 million for the nine months ended September 30, 2026, primarily driven by license and collaboration revenue. Despite this, the company recorded a net loss of $141.9 million for the same period, though this was a substantial improvement from the $395.1 million net loss in the prior year due to higher revenues and reduced research and development expenses.
Vir Biotechnology reported third-quarter 2026 financial results, ending the period with $901 million in cash and investments. The company highlighted upcoming Phase 3 data for its hepatitis delta program and the receipt of FDA Fast Track designation for its oncology candidate VIR-5500.
“We are entering an important period for Vir Bio, with meaningful catalysts across both hepatitis delta and oncology. We look forward to reporting topline ECLIPSE 1 data this quarter as we advance our goal to address the significant unmet need for patients with a therapy that can drive hepatitis delta virus to undetectable. In oncology, VIR-5500 achieved proof of concept and received FDA Fast Track designation, supporting our plans with Astellas to advance the program into pivotal trials next year. With momentum across both areas, we believe Vir Bio is well positioned to deliver meaningful value for patients and stakeholders.”
Marianne De Backer, President and Chief Executive Officer of Vir Biotechnology